The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
24/7 Wall St. on MSN20h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
And, like Lilly, Novo is also testing its semaglutide in ... Reuters reported at the time, just a few months after Zepbound’s ...
"Too often, OSA is brushed off as ‘just snoring ... Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback